Charles A. Flentge

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Dale J. Kempf, Kennan C. Marsh, Jon F. Denissen et al. · Proceedings of the National Academy of Sciences · 1995 · 551 citations · Full text

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Dale J. Kempf, Hing L. Sham, Kennan C. Marsh et al. · Journal of Medicinal Chemistry · 1998 · 204 citations · Full text

Immunology, Pharmacotherapy, Antiviral Drug +18

Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)

Rolf Wagner, John T. Randolph, Sachin Patel et al. · Journal of Medicinal Chemistry · 2018 · 53 citations · Full text

Synthesis and Biological Characterization of B-Ring Amino Analogues of Potent Benzothiadiazine Hepatitis C Virus Polymerase Inhibitors

John T. Randolph, Charles A. Flentge, Peggy Huang et al. · Journal of Medicinal Chemistry · 2009 · 39 citations · Full text

Pharmacotherapy, Antiviral Drug, Pharmaceutical Chemistry +16

2-Pyridyl P1′-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors (A-792611 and A-790742) with Potential for Convenient Dosing and Reduced Side Effects

David A. DeGoey, David J. Grampovnik, Charles A. Flentge et al. · Journal of Medicinal Chemistry · 2009 · 30 citations · Full text

Comparator Compounds, Oral Bioavailability, Bioorganic Chemistry +17